Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/20/25
End: 12/26/27
Due: 12/26/28
Phase: N/A
Priority: Normal
Start: 01/03/24
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 10/24/23
End: 02/28/25
Due: 02/28/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of BL0175 Injection in Postmenopausal Female Adults with HR-positive, Locally Advanced or Metastatic Cancer | NCT06738966 | Shanghai Best-Link Bioscience, LLC | user2@example.com | None | 2025-01-20 | 2027-12-26 | 2028-12-26 | - | - | 2025-07-14 |
| A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours | NCT06247657 | Shanghai Best-Link Bioscience, LLC | user2@example.com | None | 2024-01-03 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |
| Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | NCT05886868 | Shanghai Best-Link Bioscience, LLC | user2@example.com | None | 2023-10-24 | 2025-02-28 | 2026-02-28 | - | - | 2025-07-14 |